Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :\>~* HIV-1 infected\>~* CD4 count fewer than 300 cells/mm3 \>~* Viral load test result\>~* Absolute Neutrophil Count at least 750mm3 \>~* Hemoglobin at least 7.5 g/dL\>~* Platelet count at least 50,000/mm3\>~* Calculated creatinine clearance at least 60 mL/min\>~* A , A, and alkaline phosphatase \<= 5 times upper limit of normal\>~* total bilirubin \<= 2.5 times upper limit of normal\>~* Karnofsky performance score of 70 or higher\>~* Plans to stay in the area for the duration of the study\>~* Agrees to use acceptable forms of contraception for the duration of the study\>~Exclusion Criteria:\>~* More than 7 days exposure to ARVs (except for single-dose NVP or ZDV for any period for the purpose of pMTCT)\>~* Acute therapy for serious medical illnesses within 14 days prior to study entry\>~* Certain abnormal laboratory values\>~* Radiation therapy or chemotherapy within 45 days prior to study entry. \>~* Any immunomodulator, HIV vaccine, or other investigational therapy within 30 days prior to study entry. \>~* Current alcohol or drug abuse that, in the opinion of the site investigator, would interfere with study participation\>~* Inflamed pancreas within 3 years prior to study entry\>~* Allergy/sensitivity to any of the study drugs or their formulations\>~* Heart rate less than 40 beats/min\>~* History of untreated, active second- or third-degree heart block\>~* Currently detained in jail or for treatment of a psychiatric or physical illness\>~* Vomiting or inability to swallow medications\>~* Pregnancy\>

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZDV/3TC+EFV (Type: EXPERIMENTAL): ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
- ddI+FTC+ATV (Type: EXPERIMENTAL): ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
- TDF/FTC+EFV (Type: EXPERIMENTAL): TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz

Based on this trial design, predict the completion outcome and termination type (if applicable).